Andes Biotechnologies has received confirmation from the FDA that its IND is active so its Phase I clinical trial may proceed in the very near future.
The upcoming study will be conducted by Dr. Pamela Munster, Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, CA.
Andes 1537, the drug candidate of the company, has already been tested in animal cancer models where the therapeutic and toxicology potential of the treatment has been assessed. So far, the results are encouraging: Andes 1537 selectively destroys the tumors, indicating that this treatment specifically kills cancer cells, leaving normal cells virtually intact.
For more information, you may read this brief note (in Spanish) available in the Chilean biotech portal Redbionova.
